E ndothelial nitric oxide synthase (NOS3, eNOS) production of nitric oxide (NO) is a critical step in homeostatic regulation of vascular tone and function.
of alpha globin. Without alpha globin, NO is not efficiently scavenged, increasing diffusion to smooth muscle cells and activation of dilatory pathways.
However, the pharmacological properties of HbαX, its effect on blood flow, and its possible therapeutic effect in long-term hypertension treatment in humans is still not known. In this study, we measure hemodynamics, including flow rate and oxygen saturation, in murine resistance vasculature in response to HbαX administration and show that the mechanism of action (binding of HbαX to eNOS to disrupt complex formation) produces a sustained decrease in blood pressure with little toxicity. Importantly, we demonstrate that this mechanism is translatable to human microvasculature.
Methods

Murine and Human Subjects Declaration
All mouse procedures were performed in accordance with the University of Virginia's Institutional Animal Care and Use Committee. Human studies were approved by a University of Virginia Institutional Review Board and conformed to the principles of the Declaration of Helsinki and US Federal Regulations.
Photoacoustic Microscopy
An established multiparametric photoacoustic microscopy system 11, 12 was used to acquire oxygen saturation of hemoglobin (sO 2 ) and blood flow speed at the microscopic level in vivo. SKH1-Hr hr hairless mice were used in this study (n=3). Throughout the experiment, mice were anesthetized with 1.5% vaporized isoflurane, and body temperature was maintained using a heating pad. The ear to be imaged was gently pressed against the base of a water tank heated to 37°C. A bolus (20 mg/kg) of HbαX was administered intraperitoneally without moving the mouse. A 1 mm×2 mm field of view was imaged before the injection and at 5, 60, and 120 minutes post injection (see Figure S1 in the online-only Data Supplement). Quantification of the sO 2 and flow in the arteriole and venule of the mice was performed as described previously. 12 
Blood Pressure Measurement
Radiotelemetry blood pressure measurement and angiotensin II (AngII) osmotic mini pump insertion (Alzet, model No 2006) were performed as described. 10, 13 Briefly, the pumps were loaded with AngII with a constant infusion rate of 1000 ng/kg per minute and a 6-week maximum life span as noted by the manufacturer. Injections of saline or peptides (5 mg/kg) were performed every other day between 16:00 and 19:00 intraperitoneally. Control peptide was a scrambled sequence of HbαX (FPYFSTKLTT). 10 Mice were implanted with radiotelemetry units (Data Sciences International [DSI]). Briefly, while under isoflurane anesthesia, the catheter of the radiotelemetry unit was placed in the left carotid artery and the radiotransmitter was placed in a subcutaneous pouch on the right flank. Blood pressure was recorded for 5 min/h per day for 70 days.
Monitoring of Bone Marrow, Liver, and Kidney Toxicities
Submandibular punctures were performed every 15 days, and ≈200 μL of blood was obtained for measurement of liver and kidney function by the University of Virginia blood pathology laboratory.
Lucigenin Assay for Measuring Superoxide Production in Tissues
Measurement of tissue superoxide level was performed as previously described. 14 
Co-Immunoprecipitation of eNOS and HbαX Peptide
An eNOS/HbαX complex was visualized by immunoprecipitation and Western blotting. A full description of this protocol is available in Methods in the online-only Data Supplement.
Red Blood Cell Oxygen
Measurement of red blood cell (RBC) oxygenation was performed as described previously. 15 Blood was collected from n=3 healthy human volunteers, and each sample was tested in each treatment condition.
Recombinant Protein Expression and Purification
Protocol for eNOS protein isolation was adapted from Fischmann et al. 16 See Methods in the online-only Data Supplement for a full description.
Fluorescence Polarization Binding Assays
Fluorescein isothiocyanate (FITC)-labeled HbαX was dissolved in a small amount of water and diluted to 5 nmol/L in 5 mL of the above purification buffer. Recombinant eNOS is titrated into the wells of a 96-well plate from a maximum of 1 μmol/L. A full description of the method is available in the online-only Data Supplement.
Far Western Blotting
Far Western blotting followed the protocol of Wu et al. 17 However, our biotin-HbαX peptide was incubated directly on the membrane (in lieu of a target protein antibody) in combination with an anti-eNOS primary antibody. Secondary antibodies were used as described above for detection.
Human Ex Vivo Vasoreactivity
Under Institutional Review Board for Health Sciences Research Study 17194, human volunteers with hypertension (elevated blood pressure above 140 mm Hg systolic) had an approximate 40 mm×20 mm biopsy of adipose tissue removed from the abdomen, which was immediately placed in ice-cold KREBS buffer and arterioles dissected manually within 30 minutes of removal. The arterioles (≈50-90 μm) were cannulated, pressurized, and subject to phenylephrine cumulative dose-response curves as extensively described by us. 10, 18, 19 
Statistical Analyses
All results are presented as mean±SEM. Statistical analysis was performed by 1-way analysis of variance unless otherwise noted in the figure legends. P values <0.05 were considered significant and are denoted by asterisk.
Results
An Alpha Globin Mimetic Peptide Increases Flow in Resistance Arteries
Previously 10 we have shown that HbαX blunts vascular constriction to PE and decreases murine mean arterial pressure acutely. However, we were unable to determine whether the peptide had a corresponding effect on blood flow. Using photoacoustic microscopy, we investigated sO 2 , and blood flow (Figure 1 ) in the ear microvascular bed of SKH1 hairless mice. The abnormal strain and imaging location was used so that high-resolution images and precision measurement of these hemodynamic parameters in individual vessel segments could be obtained. Although there is an increase in sO 2 in the venule after HbαX injection, we could not detect a change in arteriole sO 2 ( Figure 1E ). However, as a result of HbαX injection, we could detect increased blood flow in both arteriole and venule ( Figure 1F) . Additional images at different time points are available in the online-only Data Supplement ( Figure S1 ).
An Alpha Globin Mimetic Peptide Can Sustain Low Blood Pressure
Although the summed acute effects of an alpha globin mimetic seem to indicate a possible effect to lower blood pressure, its long-term effect on blood pressure in a chronic model of hypertension had not been determined. For this reason, we measured blood pressure over time when mice were injected every other day with 5 mg/kg HbαX. During baseline condition (Figure 2A ), mice were normotensive, but injections of HbαX decreased blood pressure after 2 days. This shows that HbαX has an effect in nonpathological situations. During AngII-induced hypertension, the blood pressure-lowering effects of HbαX are more pronounced. The mice had AngIIinduced hypertension for 10 days before injection of HbαX. As shown in Figure 2B , chronic AngII administration resulted in hypertension, with increased systolic blood pressure from a baseline of 110 mm Hg to ≈170 mm Hg. Injection of HbαX resulted in a significant decrease of systolic blood pressure by ≈30 mm Hg. It has been proposed that prolonged AngII exposure can cause superoxide (O 2
• − ) production via eNOS dimer uncoupling, thus, contributing to hypertension by causing endothelial dysfunction. 20 In a separate group of mice, AngII was delivered via osmotic mini pumps at 1000 ng/kg per minute, and HbαX or saline was injected as described earlier. Because AngII induces superoxide generation in the kidney and vasculature, kidney and mesenteric tissues were obtained to determine superoxide levels using a lucigeninbased chemiluminescence assay. Indeed, superoxide generation was increased in both kidney ( Figure 2C ) and mesenteric tissues ( Figure 2D ) with AngII administration compared with sham. HbαX attenuated superoxide generation in the mesenteric circulation, but not in whole kidney tissues.
To test toxicity of an alpha globin peptide over such a sustained period of time, mouse blood was drawn every 15 days during the control blood pressure measurements as shown in Figure 2A , and several blood-based organ function parameters were measured. The level of hemoglobin ( Figure 3A ) and number of white blood cells ( Figure 3B ) were unchanged, suggesting that HbαX had no effect on bone marrow function. Next, we determined kidney and liver parameters and found no difference in blood urea nitrogen ( Figure 3C ), serum creatinine ( Figure 3F ), alanine and aspartate aminotransferase enzymatic activities ( Figure 3D and Figure 3E ) between HbαX and control-treated groups. The sum of these results demonstrate that the HbαX peptide itself is a potent modulator of long-term blood pressure and has no detectable kidney or liver toxicities in the 60-day period during which the peptide was administered.
An Alpha Globin Mimetic Peptide and eNOS Have Strong Affinity
Because eNOS requires homodimerization for full activity, the ability of the peptide to bind eNOS dimers was assayed with nondenaturing gel electrophoresis. In a monolayer of cultured human aortic ECs, the majority of eNOS exists as a dimeric species ( Figure 4A , left, lane 1). Incubating a biotin-tagged HbαX peptide allowed for immunodetection of the peptide with a streptavidin-conjugated antibody, as seen in Figure 4A , middle. The colocalization of the eNOS dimer and biotin bands ( Figure 4A , right) shows that eNOS and HbαX are able to form a complex when eNOS is in its active form. To quantify HbαX/ eNOS association, we show that the peptide also binds to eNOS in vitro using recombinant protein. Figure 4B shows the binding of HbαX to the oxygenase domain of eNOS (residues 64-492). Serial dilution of the larger protein eNOS (≈50 kDa) from 1 μmol/L with a constant background of 5 nmol/L FITC-labeled HbαX (≈1.5 kDa) allows us to look at the binding affinity using fluorescence polarization measurement on a microplate reader. A ligand-depleted model was used to fit the data points to calculate a K D 21 (red dashed line; Figure 4B and 4C). To confirm the binding affinity of 7±2 nmol/L, the same assay was run with 2.5 nmol/L labeled and 2.5 nmol/L unlabeled HbαX. The competition for binding site is theoretically observed as a doubling of the binding affinity because only half of the ligand is observable using the wavelength for FITC fluorophore emission and is seen experimentally as an increase to K D =13±5 nmol/L ( Figure 4C ). As a control, HbαX self-oligomerization was tested by serially diluting unlabeled HbαX from 1 μmol/L in a solution containing 5 nmol/L FITC-labeled HbαX. The lack of a hyperbolic curve in Figure 4D shows that there are no observable effects of peptide oligomerization in the sample.
Another test of the specificity of HbαX for eNOS is to determine whether there are possible effects on the other component of the endothelial NO regulatory system, hemoglobin. Because HbαX is distributed through the circulation, we investigated the effects of the peptide on hemoglobin in RBCs to confirm that there is no disruption of O 2 carrying ability. To show that HbαX was not inducing hypoxia and initiating a vasodilatory signaling cascade upstream of eNOS, we checked the partial pressure of oxygen needed for 50% saturation of hemoglobin. Using freshly isolated human blood, the addition of HbαX or a control peptide did not significantly change the oxygen p50 of hemoglobin in RBCs ( Figure 5A ). To verify the effect of HbαX in endothelium, bovine hemoglobin was serially diluted in a constant 5 nmol/L FITC-HbαX solution, and fluorescence polarization was measured. The lack of a hyperbolic curve in Figure 5B shows that there is no binding of HbαX to hemoglobin in vitro. Taken together, these results show that HbαX is predominantly binding to eNOS, and we propose that this binding is resulting in increased NO bioavailability because of reduced scavenging by alpha globin. 
Effects of the Alpha Globin Mimetic Peptide in Human Arterioles
Finally, to demonstrate the translational potential of HbαX, we tested the peptide in vitro (using recombinant human eNOS, described earlier) and ex vivo (measuring vasoreactivity of human arterioles excised from adipose biopsy samples). Figure 6A shows a Far Western blot of eNOS using HbαX as a probe. Briefly, purified recombinant human eNOS was run in a nondenaturing, low temperature polyacrylamide gel and transferred to a polyvinylidene fluoride membrane for blotting with biotin-HbαX and anti-eNOS antibodies. Fluorescent secondary antibodies show the overlap of eNOS and biotin bands, indicating that HbαX is able to bind to human eNOS. To confirm that disruption of the alpha globin/eNOS complex is relevant to human physiology, we assayed the distribution of alpha globin in the human vasculature. As previously demonstrated in mice, alpha globin is observed in the biopsied human arterioles, but not in beta globin ( Figure 6B) . Finally, the effect of peptide administration was assayed via vasoreactivity of human arterioles excised from adipose biopsies obtained from patients with hypertension (see Table S1 ). The arterioles excised from these patients were responsive to the vasoconstricting agent PE. However, when HbαX is incubated with the arteriole (5 nmol/L), the PE dose response is significantly blunted ( Figure 6C ). This is identical to the observed effect in peptide-treated C57BL/6 mice, 10 which was restored with a NO synthase inhibitor. This data provides initial evidence that HbαX may alter human peripheral resistance. When summed with the murine data above, the evidence supports a potential therapeutic value of HbαX in hypertension.
Discussion
Here, we report hemodynamic changes in mice and humans after injection of the alpha globin mimetic peptide HbαX. We hypothesize that HbαX acts as a vasodilator by displacing alpha globin from eNOS and disrupting its ability to scavenge NO at the source.
The result of increased NO levels by inhibiting scavenging can be seen using photoacoustic microscopy in Figure 1 . Using the dual optical absorbance wavelengths of oxy-and deoxyhemoglobin, total hemoglobin concentration and sO 2 are measured in live tissue. 12 Oxygen saturation of hemoglobin in the vessels is described in Figure 1 . A difference exists in the sO 2 of arteries and veins at baseline, as expected. On injection of the HbαX peptide, arterial sO 2 is unchanged (red trace) and venous sO 2 increases (blue trace) after 60 minutes. The vessel-type dependent response is consistent with physiological response to increased blood flow. Arterial oxygenation is not changed because HbαX does not change hemoglobin oxygenation dynamics as shown in Figure 5 . Venous oxygenation increases because of total increases in oxygen concentration in the tissue, so that low O 2 -induced diffusion is decreased in capillary beds. This is the result of increased blood flow in the tissues, as seen in Figure 1 . Administration of HbαX increased flow in both arterioles and venules after 60 minutes. The result of higher flow is increased O 2 distribution in the tissue surrounding the capillary beds. Although the effects were only studied in ear tissue, similar effects are expected across all resistance vasculature. Additionally, NO does not provide a majority of the vasodilatory signals in resistance vasculature under normal physiology, but with relative overproduction, the impact is likely increased.
Injections every other day were enough to decrease systolic pressure in mice at baseline and mice made hypertensive by constant infusion of AngII. Even without elevated blood pressure, the administration of HbαX decreased systolic pressure by ≈5 mm Hg (Figure 2A ). This shows that increasing NO has an effect in nonpathological contexts because there is constant regulation of NO availability by alpha globin and that disrupting the macromolecular context permits increased NO signaling in smooth Figure 2B ). AngII has been shown to increase damaging superoxide radical formation in the tissues because of activation of NADH and NADPH oxidase through its type 1 receptor. 22, 23 To address whether the large decrease in blood pressure in HbαX-treated mice in AngII hypertension is in part because of a reduction in superoxide levels, lucigenin was used to assay tissue production of O 2
• − in the kidney (a major target organ of AngII) and the resistance mesenteric vessels. In whole kidney tissues, AngII-induced superoxide generation was not attenuated by HbαX injection. This could be explained by lack of sensitivity of the assay because of the presence of many other cell types, including epithelial cells that do not express eNOS; thus, any effect of HbαX on eNOS would be difficult to detect when whole renal tissue is assessed. However, there were lower superoxide levels in the mesenteric tissue after treatment with HbαX. This could be because of a scavenging effect of superoxide by NO, forming peroxynitrite and other nitroxide species. 24 Increased NO availability by disruption of alpha globin/eNOS binding could lead to slightly lower superoxide levels in the resistance vasculature. Although the damage of free oxygen radicals produced by AngII-activated oxidases is not completely mitigated by this mechanism, some radical scavenging is likely beneficial to endothelial function. Although the decrease in blood pressure with HbαX did not return to 110 mm Hg as seen in the basal condition, a decrease in systolic blood pressure of 30 mm Hg is clinically significant and desirable in treatment. Other mechanisms of hypertension, including aldosterone disregulation or increased sympathetic drive, may also be sensitive to increases in NO production because the constrictive signaling pathways are distinct from those involved in NO action. The interplay of increased dilatory signals among the constrictive signals might be enough to shift the balance toward lower overall blood pressure.
Because HbαX was administered as a peptide injection, the toxicity readouts are important before considering human treatments. There are no detectable effects on liver or kidney function when the peptide is injected for ≤60 days. Because HbαX is a peptide chain, the breakdown products (amino acids) should be relatively inert and cleared intracellularly or from blood using endogenous protein breakdown machinery. Critically, the injection of the mimetic peptide did not increase white blood cell count, indicating no inflammatory response to the peptide ( Figure 3B ). Because the sequence is found in endogenous hemoglobin, it is unlikely that antibodies would be developed against the sequence. Measures of liver and kidney function (assayed by urea, alanine aminotransferase, aspartate aminotransferase, and plasma creatinine levels; Figure 3C -3F) showed no difference between saline, control peptide, or HbαX-treated mice, illustrating no detectable toxicity and its potential as a novel therapeutic agent in the treatment of hypertension by increasing NO availability in ECs.
To confirm the proposed mechanism of HbαX on the disruption of the alpha globin/eNOS complex, 10 we assayed the binding of HbαX and eNOS in vitro. In cultured ECs, HbαX immunoprecipitates with dimeric eNOS protein ( Figure 4A) , showing that eNOS can remain in its active oligomeric state when the peptide is bound. An active eNOS enzyme is critical for increased NO availability with HbαΧ treatment because the peptide works to disrupt the formation of an alpha globin/eNOS macromolecular complex. Our model suggests that the alpha globin mimetic peptide HbαX competes with the full alpha globin chain for a binding pocket on the oxygenase domain of eNOS, and previous work has shown fluorescently labeled HbαX colocalized with alpha globin in the MEJ, where a functional pool of eNOS is located in ECs. 3, 9, 10 These results suggest proximity of the functional parts, but do not directly show binding. We use fluorescence polarization assays to prove that HbαX binds to eNOS and determine the binding affinity. In our experiment, we determined that HbαX Figure 6 . An alpha globin mimetic peptide significantly reduces hyperconstriction in arterioles from human patients with hypertension. A, Far Western blotting for recombinant human eNOS oxygenase domain on a nondenaturing gel using antieNOS and biotin-HbαX probes and corresponding secondary antibodies for fluorescent detection. Left lane serves as a molecular weight marker, but it is not used to estimate molecular weight because of the nondenaturing condition of the gel. The samples were run in duplicate. B, Western blot of the expression of alpha globin without its beta globin partner is confirmed in human arterioles, and a 10-fold dilution of RBC samples is used as a positive control for alpha and beta globin chains. Note the lack of alpha globin in aorta. Arrowheads for CD31 indicate 100 kDa, and alpha and beta globin indicate 10 kDa. C, Resistance arterioles (≈100 μm in diameter) isolated from human adipose tissue biopsies were cannulated and subject to phenylephrine (PE) cumulative dose-response curves in the absence (black) or presence (blue) of 5 μmol/L HbαX (n=4). *P<0.05, **P<0.01 using 2-way ANOVA and a Bonferroni post-test. AR indicates aorta; art, arteriole; eNOS, endothelial nitric oxide synthase; IB, immunoblot; IP, immunoprecipitation; and RBC, red blood cell.
and eNOS bind with low nanomolar affinity ( Figure 4B ). As a validation of this result, half of the fluorescently labeled HbαX in the ligand buffer was replaced with unlabeled HbαX. This competition experiment effectively doubles the observed binding affinity because only labeled peptide (now at half the concentration) is able to be measured and is competing for the same number of binding sites. Roughly, a doubling of the binding affinity is observed in this mode ( Figure 4C ). This is not an effect attributable to HbαX oligomerization because there is no observable binding curve from data in Figure 4D .
There is considerable evidence that NO can also be modulated by RBCs, as well as the endothelium. It has been elegantly demonstrated that NO production in erythrocytes can occur either by nitrite conversion or by eNOS in the RBCs. [25] [26] [27] [28] [29] [30] It is possible that free NO availability in the circulating cells is regulated by a similar mechanism as in ECs because of the vast amounts of hemoglobin present directly adjacent to a membrane-bound NOS enzyme. Overproduction of NO in RBCs might lead to higher levels of methemoglobin within the cells and negatively affect the O 2 carrying capacity of the RBCs. A reduced O 2 capacity for RBCs might trigger a hypoxic response leading to the observed vasodilation in vivo. To determine whether HbαX application could increase NO production and higher p50 values for isolated RBCs, freshly isolated human blood was incubated with concentrations of HbαX much higher (30 μmol/L; Figure 5 ) than would be encountered with therapeutic administration. Even with this level, there was no effect on the p50 of RBC hemoglobin in intact RBCs. With this result, we think that the effects on RBC eNOS are not the major contributor to the vasodilatory response seen in our system. However, the systems for NO bioavailablity in RBCs may be inherently different in terms of a signaling mechanism, or the peptide may not have been able to penetrate the membrane of the RBC.
The translational capacity of HbαX to disrupt the alpha globin/eNOS complex to increase NO production is shown in Figure 6 . HbαX is able to bind to the oxygenase domain of eNOS, and this interaction is physiologically relevant in human vasculature. The expression of alpha globin in arteriole ECs (but not in the aortic root) shows that disruption of the alpha globin/eNOS interaction predominantly occurs in resistance vasculature, where blood pressure is controlled. The effect of HbαX can be observed ex vivo on individual arterioles using pressure myography. After incubation with HbαX, blunted vasoconstriction to PE is observed in arterioles excised from humans with hypertension (Table S1 ). Thus, in the context of systemic high blood pressure, increasing local NO signaling in the resistance vasculature might provide therapeutic benefit. This result provides a base for novel treatments of hypertension by increasing endogenous NO production.
Other strategies exist for increasing production of NO in vivo by removing an inhibitory pathway for eNOS. One wellcharacterized inhibitory binding partner for eNOS is caveolin-1, the main coat protein of caveolae. [31] [32] [33] [34] Interestingly, a peptide mimicking the eNOS-binding sequence of caveolin, Cav1 [6] [7] [8] , and HbαX share some sequence similarity. Table  S2 shows the sequences of the Cav1 6 peptide and HbαX 10 for comparison. Of note, the peptides are composed of both polar and hydrophobic residues, which indicate both buried and solvent-exposed side chains in the binding sequence. The intracellular eNOS-binding interface of caveolin interacts with the calmodulin-binding motif between the oxygenase and reductase domains of eNOS to prevent activation and NO production. 34 The similarity of the threonine-rich sequences with surrounding hydrophobic residues may be coincidental, but provides a direction for further study of the binding location for alpha globin/HbαX on eNOS.
There are further questions raised by these results. Our previous work has used an eNOS inhibitor, l-nitroarginine methyl ester, to show that blunted response to PE is an NO-dependent phenomenon.
9,10 A lack of human volunteers for biopsy prevented tests of l-nitroarginine methyl ester sensitivity in human arterioles, a limitation of using human samples in research. The dynamics of the alpha globin/eNOS interaction is also of importance. The binding affinity, k on , and k off rates for the full alpha globin chain binding to eNOS are yet to be determined and will provide evidence for a model of static or transient interaction in the scavenging of NO by alpha globin. Having a model of the alpha globin/eNOS interaction that includes dynamics will be useful in further modification of the HbαX peptide for better pharmacokinetics.
In conclusion, this study provides evidence for modulation of blood flow and decreasing blood pressure using an alpha globin mimetic peptide to prevent NO scavenging. The peptide, HbαX, disrupts an alpha globin/eNOS macromolecular complex by binding to eNOS and increases blood flow and oxygen saturation in vivo. HbαX does not seem to affect bone marrow, liver or kidney function. The target specificity of the peptide prevents negative interactions with endogenous hemoglobin and enhances NO signaling, leading to vasodilatory effects to lower blood pressure.
Perspectives
This work characterizes an alpha globin mimetic peptide and its role in decreasing vascular resistance and increasing blood flow. By increasing NO bioavailability, HbαX is a potent therapeutic both for acute hypertensive crises (by increasing tissue oxygenation and blood flow in resistance arteries) and long-term treatment of hypertension (because of its low toxicity and sustained decrease in blood pressure). 
Online Data Supplement for
Co-immunoprecipitation of eNOS and HbαX peptide
A monolayer of human aortic endothelial cells (hAoECs) was lysed in non-reducing RIPA buffer and incubated at 4°C with excess biotin-HbαX for 2 hours. Rabbit anti-eNOS antibody was added and incubation proceeded at 4°C overnight. 20 μL of Sheep-antirabbit Dynabeads was added the next day and allowed to incubate on ice for 2 hours. The Dynabeads were washed with buffer and split for gel samples. The first fraction was diluted with non-reducing running buffer and added directly to gel lanes. The other fraction was subjected to elution in low-pH conditions without reducing agents before nonreducing running buffer was added. Samples were run on a Tris-glycine gel kept on ice using a constant current of 20 mA to prevent significant heating, and transferred to a PVDF membrane. The membrane was blocked with TBS/3%BSA before addition of rabbit anti-eNOS primary antibody. Fluorescent detection was achieved with anti-rabbit 700nm (eNOS) and avidin 800nm (biotin) on a Licor Odyssey Imager.
Recombinant eNOS growth and purification
Briefly, E. coli (strain UT5600 1 ) were transformed with a pGEX-2T vector coding for eNOS residues 66-492 (Uniprot: P29474). 500 mL GC media (20 g/L casein hydrolysate*, 5 g/L potassium phosphate (pH = 7)*, 10% v/v glycerol*, 4 mmol/L MgSO4*, 100 ug/mL ampicillin, 60 ug/mL levulinic acid, 5 μmol/L hemin (dissolved in DMSO), * denotes autoclaved reagent) was prepared in 2L baffled-bottom flasks and inoculated with 10mL overnight cultures of bacteria containing the pGEX plasmid (above) and set to shake at 37 o C and 225 rpm. At OD600 = 0.8, flasks were induced with 1mM IPTG and the temperature was reduced to 25 o C. After 14 hours, bacteria were harvested from media by centrifugation at 500 x g and pellets were frozen for >24 hours at -20 o C. Eluant from the thrombin cleavage reaction was passed over benzamidine agarose equilibrated with purification buffer to remove the protease. The solution containing eNOS was concentrated with a 30,000 MWCO centrifuge filter (Millipore) and was run over a size exclusion column for further purification.
Fluorescence Polarization Assay
In 700 μL, eNOS is diluted to 1 μmol/L in purification buffer containing 5 nmol/L HbαX peptide. In an opaque 96-well plate, 100 μL of 5 nmol/L HbαX solution was pipetted into wells 2-11 in triplicate rows. In the first well of the three rows, 200 μL of 1 μmol/L eNOS/5 nmol/L HbαX solution was added to the empty well. 100 μL of well 1 was serially diluted into wells 2-12 and the reaction was incubated at room temperature for 30 minutes. Fluorescence polarization was measured using a SpectraMaxM5 fluorescent plate reader using a top read configuration. Excitation of FITC fluorophore used 495 nm light, and emission was read at 519 nm. The data was normalized to highest polarization point and fit with a ligand depleted model 2 . For competition experiment, Figure 4B , the only change is in HbαX concentrations: the 5 nmol/L total ligand stays constant, but in the solution, 2.5 nmol/L is fluorescently labeled and 2.5 nmol/L is unlabeled. In Figure 4C , 5nmol/L labeled HbαX was used as the dilution buffer for serial dilution of 1 μmol/L unlabeled HbαX.
